Cell-free supernatant of Levilactobacillus brevis (RAMULAB51) from coconut inflorescence sap (Neera) enhances glucose uptake and PPAR-γ in 3T3-L1 adipocytes and inhibits α-glucosidase and α-amylase

IntroductionLactic acid bacteria are prized for their probiotic benefits and gut health improvements. This study assessed five LAB isolates from Neera, with RAMULAB51 (Levilactobacillus brevis, GenBank ON171686.1) standing out for its high hydrophobicity, auto-aggregation, antimicrobial activity, an...

Full description

Saved in:
Bibliographic Details
Main Authors: Chandana Kumari V B, Ramith Ramu, Prithvi S. Shirahatti, Perwez Alam, Ling Shing Wong
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Microbiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2024.1497023/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846111148324159488
author Chandana Kumari V B
Ramith Ramu
Prithvi S. Shirahatti
Perwez Alam
Ling Shing Wong
author_facet Chandana Kumari V B
Ramith Ramu
Prithvi S. Shirahatti
Perwez Alam
Ling Shing Wong
author_sort Chandana Kumari V B
collection DOAJ
description IntroductionLactic acid bacteria are prized for their probiotic benefits and gut health improvements. This study assessed five LAB isolates from Neera, with RAMULAB51 (Levilactobacillus brevis, GenBank ON171686.1) standing out for its high hydrophobicity, auto-aggregation, antimicrobial activity, and enzyme inhibition. It evaluated RAMULAB51’s potential in probiotics and diabetes management, focusing on its effects on digestive enzyme inhibition, glucose uptake, and adipocyte function.MethodsIsolates were characterized by Gram staining, catalase reaction, growth at 37°C, and tolerance to phenol, pH, and gastrointestinal conditions. Molecular identification using 16S rRNA sequencing. Evaluations included hydrophobicity, auto-aggregation, HT-29 cell line adhesion, antimicrobial activity, and antibiotic susceptibility. Enzyme inhibition was measured for α-glucosidase and α-amylase using cell-free supernatant, cell extract, and intact cells. Adipogenesis was assessed through Oil-Red O staining, gene expression analysis (PPAR-γ, C/EBPα, Adiponectin, Glut-4, FAS), and glucose uptake assays on 3T3-L1 cells.ResultsAll isolates showed good tolerance to pH (≤9.15 CFU/ml), phenol (≤9.90 CFU/ml), hydrophobicity (≤78.14%), and auto-aggregation (≤92.23%). RAMULAB51 demonstrated the highest tolerance, hydrophobicity, and auto-aggregation. It strongly co-aggregated with Micrococcus luteus and Bacillus subtilis, showing significant antimicrobial activity with a 24 mm inhibition zone against Micrococcus luteus. All isolates were sensitive to Ampicillin, Azithromycin, Streptomycin, and Tetracycline, but resistant to Methicillin and Vancomycin. RAMULAB51 demonstrated the highest enzyme inhibition: α-glucosidase (68.45% CFS, 60.18% CE, 42.15% IC) and α-amylase (80.74% CFS, 61.23% CE, 35.12% IC). By inhibiting these digestive enzymes, RAMULAB51 reduces the conversion of carbohydrates into glucose, thereby decreasing blood glucose levels. This reduction in circulating glucose subsequently influences adipocyte function, as evidenced by the enhanced glucose uptake (1000 µg/mL) and upregulation of PPAR-γ, C/EBPα, Adiponectin, and Glut-4, alongside the downregulation of FAS.ConclusionThe study highlights RAMULAB51’s potential for improving glucose and lipid metabolism. Further, in vivo research is needed to explore its full therapeutic benefits. These findings confirm RAMULAB51’s significant probiotic potential and its promise for diabetes management, warranting further clinical investigation.
format Article
id doaj-art-ea7082d433d94c98b6baaf56af2f6022
institution Kabale University
issn 1664-302X
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Microbiology
spelling doaj-art-ea7082d433d94c98b6baaf56af2f60222024-12-23T12:55:34ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2024-12-011510.3389/fmicb.2024.14970231497023Cell-free supernatant of Levilactobacillus brevis (RAMULAB51) from coconut inflorescence sap (Neera) enhances glucose uptake and PPAR-γ in 3T3-L1 adipocytes and inhibits α-glucosidase and α-amylaseChandana Kumari V B0Ramith Ramu1Prithvi S. Shirahatti2Perwez Alam3Ling Shing Wong4Department of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysore, Karnataka, IndiaDepartment of Biotechnology and Bioinformatics, JSS Academy of Higher Education and Research, Mysore, Karnataka, IndiaSt. Joseph’s College for Women, Rammanahalli, Karnataka, IndiaDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaFaculty of Health and Life Sciences, INTI International University, Nilai, MalaysiaIntroductionLactic acid bacteria are prized for their probiotic benefits and gut health improvements. This study assessed five LAB isolates from Neera, with RAMULAB51 (Levilactobacillus brevis, GenBank ON171686.1) standing out for its high hydrophobicity, auto-aggregation, antimicrobial activity, and enzyme inhibition. It evaluated RAMULAB51’s potential in probiotics and diabetes management, focusing on its effects on digestive enzyme inhibition, glucose uptake, and adipocyte function.MethodsIsolates were characterized by Gram staining, catalase reaction, growth at 37°C, and tolerance to phenol, pH, and gastrointestinal conditions. Molecular identification using 16S rRNA sequencing. Evaluations included hydrophobicity, auto-aggregation, HT-29 cell line adhesion, antimicrobial activity, and antibiotic susceptibility. Enzyme inhibition was measured for α-glucosidase and α-amylase using cell-free supernatant, cell extract, and intact cells. Adipogenesis was assessed through Oil-Red O staining, gene expression analysis (PPAR-γ, C/EBPα, Adiponectin, Glut-4, FAS), and glucose uptake assays on 3T3-L1 cells.ResultsAll isolates showed good tolerance to pH (≤9.15 CFU/ml), phenol (≤9.90 CFU/ml), hydrophobicity (≤78.14%), and auto-aggregation (≤92.23%). RAMULAB51 demonstrated the highest tolerance, hydrophobicity, and auto-aggregation. It strongly co-aggregated with Micrococcus luteus and Bacillus subtilis, showing significant antimicrobial activity with a 24 mm inhibition zone against Micrococcus luteus. All isolates were sensitive to Ampicillin, Azithromycin, Streptomycin, and Tetracycline, but resistant to Methicillin and Vancomycin. RAMULAB51 demonstrated the highest enzyme inhibition: α-glucosidase (68.45% CFS, 60.18% CE, 42.15% IC) and α-amylase (80.74% CFS, 61.23% CE, 35.12% IC). By inhibiting these digestive enzymes, RAMULAB51 reduces the conversion of carbohydrates into glucose, thereby decreasing blood glucose levels. This reduction in circulating glucose subsequently influences adipocyte function, as evidenced by the enhanced glucose uptake (1000 µg/mL) and upregulation of PPAR-γ, C/EBPα, Adiponectin, and Glut-4, alongside the downregulation of FAS.ConclusionThe study highlights RAMULAB51’s potential for improving glucose and lipid metabolism. Further, in vivo research is needed to explore its full therapeutic benefits. These findings confirm RAMULAB51’s significant probiotic potential and its promise for diabetes management, warranting further clinical investigation.https://www.frontiersin.org/articles/10.3389/fmicb.2024.1497023/fullNeeraprobioticsType 2 Diabetes Mellitusα-glucosidaseα-amylasePPAR-γ activation
spellingShingle Chandana Kumari V B
Ramith Ramu
Prithvi S. Shirahatti
Perwez Alam
Ling Shing Wong
Cell-free supernatant of Levilactobacillus brevis (RAMULAB51) from coconut inflorescence sap (Neera) enhances glucose uptake and PPAR-γ in 3T3-L1 adipocytes and inhibits α-glucosidase and α-amylase
Frontiers in Microbiology
Neera
probiotics
Type 2 Diabetes Mellitus
α-glucosidase
α-amylase
PPAR-γ activation
title Cell-free supernatant of Levilactobacillus brevis (RAMULAB51) from coconut inflorescence sap (Neera) enhances glucose uptake and PPAR-γ in 3T3-L1 adipocytes and inhibits α-glucosidase and α-amylase
title_full Cell-free supernatant of Levilactobacillus brevis (RAMULAB51) from coconut inflorescence sap (Neera) enhances glucose uptake and PPAR-γ in 3T3-L1 adipocytes and inhibits α-glucosidase and α-amylase
title_fullStr Cell-free supernatant of Levilactobacillus brevis (RAMULAB51) from coconut inflorescence sap (Neera) enhances glucose uptake and PPAR-γ in 3T3-L1 adipocytes and inhibits α-glucosidase and α-amylase
title_full_unstemmed Cell-free supernatant of Levilactobacillus brevis (RAMULAB51) from coconut inflorescence sap (Neera) enhances glucose uptake and PPAR-γ in 3T3-L1 adipocytes and inhibits α-glucosidase and α-amylase
title_short Cell-free supernatant of Levilactobacillus brevis (RAMULAB51) from coconut inflorescence sap (Neera) enhances glucose uptake and PPAR-γ in 3T3-L1 adipocytes and inhibits α-glucosidase and α-amylase
title_sort cell free supernatant of levilactobacillus brevis ramulab51 from coconut inflorescence sap neera enhances glucose uptake and ppar γ in 3t3 l1 adipocytes and inhibits α glucosidase and α amylase
topic Neera
probiotics
Type 2 Diabetes Mellitus
α-glucosidase
α-amylase
PPAR-γ activation
url https://www.frontiersin.org/articles/10.3389/fmicb.2024.1497023/full
work_keys_str_mv AT chandanakumarivb cellfreesupernatantoflevilactobacillusbrevisramulab51fromcoconutinflorescencesapneeraenhancesglucoseuptakeandppargin3t3l1adipocytesandinhibitsaglucosidaseandaamylase
AT ramithramu cellfreesupernatantoflevilactobacillusbrevisramulab51fromcoconutinflorescencesapneeraenhancesglucoseuptakeandppargin3t3l1adipocytesandinhibitsaglucosidaseandaamylase
AT prithvisshirahatti cellfreesupernatantoflevilactobacillusbrevisramulab51fromcoconutinflorescencesapneeraenhancesglucoseuptakeandppargin3t3l1adipocytesandinhibitsaglucosidaseandaamylase
AT perwezalam cellfreesupernatantoflevilactobacillusbrevisramulab51fromcoconutinflorescencesapneeraenhancesglucoseuptakeandppargin3t3l1adipocytesandinhibitsaglucosidaseandaamylase
AT lingshingwong cellfreesupernatantoflevilactobacillusbrevisramulab51fromcoconutinflorescencesapneeraenhancesglucoseuptakeandppargin3t3l1adipocytesandinhibitsaglucosidaseandaamylase